Accession Therapeutics’ Trocept approach enables the company to design novel highly targeted treatments with the potential to eradicate all cells in a tumour, regardless of diversity.

This enormous increase in the ability to target tumours and wipe out cancer cells eliminates many of the drawbacks of current immunotherapies.

Accession Therapeutics is the first company to have engineered a viral point of entry to cancer cells while bypassing healthy cells.